Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 168 Precursor Cell Lymphoblastic Leukemia-Lymphoma 33 Recurrence 28 Leukemia 24 Vomiting 23 Neoplasms, Plasma Cell 20 Lymphoma 18 Neoplasms 16 Nausea 13 Burkitt Lymphoma 11 Prostatic Neoplasms 8 Immunoglobulin Light-chain Amyloidosis 7 Carcinoma, Non-Small-Cell Lung 6 Lymphoma, Follicular 5 Lung Neoplasms 5 Hodgkin Disease 5 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, Non-Hodgkin 4 Leukemia, Biphenotypic, Acute 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Paraproteinemias 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large B-Cell, Diffuse 3 Fallopian Tube Neoplasms 3

Interventions

enzalutamide 2 cabazitaxel 2 Prednisone 2 Androgen Antagonists 2 fludrocortisone acetate 1 darolutamide 1 XRP6258 1 Radiosurgery 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hydrocortisone 1 Granulocyte Colony-Stimulating Factor 1 Docetaxel 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostate Cancer Metastatic × Dexamethasone × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡